BlackRock’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$304M Buy
20,868,362
+910,860
+5% +$8.79M ﹤0.01% 1537
2026
Q1
$148M Buy
19,957,502
+496,153
+3% +$5.22M ﹤0.01% 1861
2025
Q4
$229M Buy
19,461,349
+162,420
+0.8% +$1.75M ﹤0.01% 1595
2025
Q3
$149M Sell
19,298,929
-125,659
-0.6% -$880K ﹤0.01% 1842
2025
Q2
$142M Sell
19,424,588
-439,838
-2% -$3.55M ﹤0.01% 1824
2025
Q1
$189M Sell
19,864,426
-379,241
-2% -$4.74M ﹤0.01% 1630
2024
Q4
$334M Buy
20,243,667
+332,324
+2% +$5.16M 0.01% 1362
2024
Q3
$294M Buy
19,911,343
+241,269
+1% +$3.78M 0.01% 1439
2024
Q2
$273M Sell
19,670,074
-180,790
-0.9% -$2.56M 0.01% 1409
2024
Q1
$312M Sell
19,850,864
-130,129
-0.7% -$2.01M 0.01% 1339
2023
Q4
$323M Sell
19,980,993
-121,915
-0.6% -$1.99M 0.01% 1323
2023
Q3
$247M Sell
20,102,908
-673,304
-3% -$10M 0.01% 1401
2023
Q2
$334M Sell
20,776,212
-532,168
-2% -$8.77M 0.01% 1212
2023
Q1
$371M Sell
21,308,380
-625,097
-3% -$8.9M 0.01% 1127
2022
Q4
$203M Buy
21,933,477
+824,295
+4% +$7.68M 0.01% 1520
2022
Q3
$182M Buy
21,109,182
+79,055
+0.4% +$785K 0.01% 1548
2022
Q2
$171M Buy
21,030,127
+1,440,078
+7% +$13.7M 0.01% 1644
2022
Q1
$238M Buy
19,590,049
+261,795
+1% +$5.51M 0.01% 1538
2021
Q4
$659M Buy
19,328,254
+569,039
+3% +$22.3M 0.02% 823
2021
Q3
$905M Buy
18,759,215
+36,710
+0.2% +$1.7M 0.03% 621
2021
Q2
$846M Sell
18,722,505
-18,621
-0.1% -$825K 0.02% 673
2021
Q1
$904M Buy
18,741,126
+1,494,556
+9% +$77.8M 0.03% 637
2020
Q4
$929M Buy
17,246,570
+861,490
+5% +$38.9M 0.03% 561
2020
Q3
$604M Sell
16,385,080
-291,155
-2% -$10.8M 0.02% 650
2020
Q2
$517M Buy
16,676,235
+1,364,731
+9% +$37.8M 0.02% 697
2020
Q1
$423M Sell
15,311,504
-277,628
-2% -$8.32M 0.02% 699
2019
Q4
$456M Buy
15,589,132
+273,141
+2% +$6.5M 0.02% 856
2019
Q3
$293M Buy
15,315,991
+390,664
+3% +$9.16M 0.01% 1130
2019
Q2
$327M Buy
14,925,327
+1,100,263
+8% +$24.1M 0.01% 1066
2019
Q1
$283M Buy
13,825,064
+8,305,417
+150% +$144M 0.01% 1153
2018
Q4
$69.6M Buy
5,519,647
+440,621
+9% +$6.57M ﹤0.01% 2037
2018
Q3
$78M Buy
5,079,026
+929,697
+22% +$12.9M ﹤0.01% 2129
2018
Q2
$54.4M Buy
4,149,329
+184,386
+5% +$2.03M ﹤0.01% 2309
2018
Q1
$32.4M Buy
3,964,943
+12,147
+0.3% +$98.4K ﹤0.01% 2511
2017
Q4
$35M Buy
3,952,796
+54,998
+1% +$507K ﹤0.01% 2480
2017
Q3
$43.4M Buy
3,897,798
+476,681
+14% +$4.64M ﹤0.01% 2368
2017
Q2
$30.7M Buy
3,421,117
+90,861
+3% +$721K ﹤0.01% 2538
2017
Q1
$26.3M Buy
3,330,256
+3,326,005
+78,241% +$27.1M ﹤0.01% 2601
2016
Q4
$36K Sell
4,251
-484
-10% -$4.15K ﹤0.01% 3070
2016
Q3
$39K Buy
4,735
+317
+7% +$2.66K ﹤0.01% 3081
2016
Q2
$35K Buy
4,418
+722
+20% +$5.79K ﹤0.01% 3079
2016
Q1
$25K Buy
3,696
+2,272
+160% +$15K ﹤0.01% 2743
2015
Q4
$11K Hold
1,424
﹤0.01% 2849
2015
Q3
$8K Hold
1,424
﹤0.01% 2833
2015
Q2
$8K Buy
+1,424
New +$7.34K ﹤0.01% 2923

Other funds holding NEO

BlackRock's NEO Position: Q2 2026 in Review

BlackRock increased its NeoGenomics (NEO) stake by 4.6% in Q2 2026, buying an estimated $8.79M and bringing the position to 20,868,362 shares worth $304M. The position accounts for ﹤0.01% of the portfolio, ranked #1537.

BlackRock first reported a position in NEO in Q2 2015 and has held it in 45 quarters since. The position peaked at $929M in Q4 2020. 266 funds tracked by Wall St. Rank hold NEO as of Q2 2026.

  • BlackRock held 20,868,362 shares of NeoGenomics worth $304M as of Q2 2026.
  • BlackRock bought 910,860 NeoGenomics shares in Q2 2026, an estimated $8.79M.
  • NeoGenomics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1537 holding.
  • BlackRock first reported a position in NeoGenomics in Q2 2015 and has held it in 45 quarters since.
  • BlackRock's NeoGenomics position peaked at $929M in Q4 2020.
  • 266 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.